What we're reading, February 12, 2016: the former Kentucky governor is looking to block the current governor's plans to dismantle Kynect; Senator Orrin Hatch speaks out against Medicare negotiation of drug prices; and the link between Zika and microcephaly is growing stronger.
In Kentucky, the former governor, Steve Beshear, is launching an effort to thwart the efforts of the new Republican governor, Matt Bevin, who is starting the process to dismantle the state’s health insurance exchange, Kynect. Beshear announced that an online campaign will educate voters about what is happening to healthcare in Kentucky, according to ABC News. During Beshear’s time as governor, he issued an executive order to expand Medicaid and establish the state exchange.
While some presidential hopefuls, like Hillary Clinton, Bernie Sanders, and Donald Trump, are calling for Medicare to have the ability to negotiate drug prices, Senator Orrin Hatch is firmly against it, noting that Medicare negotiation wouldn’t be “a big saver.” Washington Examiner reported that the senator asked HHS Secretary Sylvia M. Burwell if her agency had worked with the president on an executive order that would allow the government to negotiate prices. Hatch is worried the president would issue such an executive order, which Hatch called a “violation of the law.”
The link between the Zika virus and microcephaly is growing stronger, CDC Director Tom Frieden, MD, testified before the Senate Appropriations Committee. Studies of babies that died within 24 hours found they had microcephaly, according to the Washington Times. Dr Frieden and Anthony Fauci, MD, infectious disease director at the National Institutes of Health, asked lawmakers to approve the president’s request for emergency funding to fight Zika.
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Downward Morbidity, Mortality Trends Discovered Among Patients With Ovarian Cancer, Liver Metastases
April 24th 2024This study indicates a declining trend in morbidity and mortality rates among patients with ovarian cancer and liver metastases, highlighting the efficacy of surgery and chemotherapy in improving survival outcomes.
Read More
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More